Open Door Salon

Konstantina Katcheves is Chief Business & Strategy Officer at Acadia Pharmaceuticals. Former SVP at Bristol-Myers Squibb. Led BMS through the Karuna Bio and RayzeBio acquisitions in a single month. Now at Acadia building rare disease capabilities. Daphne Karydas is President & CFO of Flare Therapeutics. Former CFO at Syndax, Head of Corporate Strategy at Allergan, and 15+ years on Wall Str...

Jeff Fischer is Co-Founder and President of Longhorn Vaccines and Diagnostics — developing monoclonal antibodies that target chronic inflammation upstream, before it starts. Steve Butts is Co-Founder and CEO of Arrivo BioVentures. His lead drug for depression works in women but not men. Then investors asked: "Is there really a market for that?" In Today's Episode: Longevity isn't...

Tina Valbh, BS Pharm, RPh is a pharmacist with 28 years in life sciences — Managing Partner at Pharma Connect and founder of Tina's Warriors. She builds patient access programs. Then she got cancer — and discovered none of it worked the way the slide decks said. Karla Loken, DO, OBGYN, FACOOG practiced OB-GYN for 20+ years before leading clinical development and medical affairs roles at Hologic, R...

Matt Hewitt is CTO of the Manufacturing Business Division at Charles River Laboratories. Jeff Holder is Partner and Managing Director at LEK Consulting, advising biopharma and investors on cell and gene therapy strategy since the first CAR-T approvals in 2017. In Today's Episode: JPM 2026: Is cell & gene therapy interest real or cooling? Why manufacturing cost isn't the real barrier to...

Katie Schubert is President & CEO of the Society for Women's Health Research — 35+ years advocating for sex differences research. Former Capitol Hill staffer. Her goal: make women's health so mainstream that her organization goes out of business. Joanna Stickler is VP of Health Policy & External Affairs at Roche Diagnostics. Former public health professional. Her mantra: we haven&#...

Frank Watanabe is the President and CEO of Arcutis Biotherapeutics, a dermatology biotechnology company based in Los Angeles. He's also the Vice Chairman of BIO. Frank spent 30 years in biopharma after a prior career in national security — he stumbled into the industry at Eli Lilly and stayed for the mission. Josh Fessel is a physician-scientist who most recently served as Chief Medical Office...

Andy Holt is the Chief Commercial Officer at Viralgen Vector Core, a company specializing in the contract manufacture of AAV gene therapies. A self-described "really bad molecular biologist" who moved to the commercial side, Andy has spent 18 years in cell and gene therapy, including a stint as VP at AskBio before its acquisition by Bayer. Phil Vanek is the Chief Commercialization Office...

Colin Zick is a Partner at Foley Hoag, where he co-chairs both the Health Care Compliance practice and the Privacy & Data Security practice. With over 30 years of experience navigating healthcare regulation and cybersecurity, Colin has seen administrations come and go—and knows that the fundamentals of compliance never change, even when everything else does. Anne Herold Li is a Shareholder at...

Chris Bardon is the Managing Partner at MPM BioImpact, a dedicated biotech investment firm working across private and public markets. A Harvard-trained physician who completed her residency at Brigham and Women's Hospital, Chris has spent over 20 years in biotech investing, including time at Fidelity before launching her own fund. She also serves on the board of the American Association for Cancer...